Pharma Pulse 7/17/24: OpenAI Scale Ranks Progress Toward ‘Human-Level’ Problem Solving, Increased Use of GLP-1 Drugs Adds to Navitus’ Drug Spend & more

How Cellarity's AI/ML Approach Differs

In this part of his Pharmaceutical Executive video interview, Fabrice Chouraqui, CEO of Cellarity, discusses how their AI/ML approach differs and the advantages it offers in terms of uncovering novel treatment opportunities.

Increased Use of GLP-1 Drugs Adds to Navitus’ Drug Spend for 2023

The switch to biosimilars helped Navitus clients offset increased utilization in the non-specialty category and the introduction of higher-cost specialty drugs.

OpenAI Scale Ranks Progress Toward ‘Human-Level’ Problem Solving

The company believes its technology is approaching the second level of five on the path to artificial general intelligence.

Life Sciences Firms Adopt Tools to Modernize Clinical Trials

Technologies that enable decentralized clinical trials and other new practices are transforming the global life sciences industry, according to a new research report published today by Information Services Group.

Cencora on LinkedIn

We brought together the best minds in the industry to discuss the best practices and challenges in the cell and gene therapy space at our ThinkLive Summit.

Listen to VP of Cell and Gene Therapy Lung-I Cheng speak about the inaugural event in a recent Pharmaceutical Commerce Magazine interview: https://ow.ly/Wk5s50SCn1g

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs